Tuesday June 11, 9:45–11:45. Room N-Hall E, Moscone Center, San Francisco, California
- Introduction. John B. Buse, MD, PhD
- Oral semaglutide: How well does it work and in what settings? Vanita R. Aroda, MD
- Oral semaglutide: How does it compare to alternatives? Richard E. Pratley, MD
- PIONEER 6: Trial design and baseline characteristics. Stephen C. Bain, MA, MD, FRCP
- PIONEER 6: Cardiovascular outcomes. Mansoor Husain, MD, FRCPC
- PIONEER 6: Metabolic and safety outcomes. Ofri Mosenzon, MD, MSc
- Summary. John B. Buse, MD, PhD
- Independent commentary. Vivian Fonseca, MD
An exciting time for the GLP-1RA class with the introduction of the first oral preparation. The PIONEER program will provide safety and efficacy data across a broad range of patients as well as provide us with insight into the cardiovascular safety in the PIONEER 6 trial.
More on the this trial
- Clinical study overview | The PIONEER 6 trial
- News story | PIONEER 3: Oral semaglutide proves worth against sitagliptin
- Quick guide | Round-up of the GLP-1 receptor agonist CV outcome trials
- External link | Published design and baseline characteristics of PIONEER 6